Latest Industry Insights

Dr. Adam Crowe sheds light on why a newly discovered reactive impurity is detrimental to mRNA function and how it can be detected more accurately.

Dr. Mary McBride and Professor Chris Elliott, world-renowned for his work in food safety and authenticity, discuss his career to date, his passion for food safety, the projects his team are working on and the future.

This article discusses how library-based approaches in quantitative proteomics can increase the sensitivity and accuracy of such detection systems.

In this article, we will discuss how innovative HPLC with charged aerosol detection technology can tackle common analytical challenges, allowing robust characterization of the composition of the lipid nanoparticles in the formulation and accurate determination of impurities at the required regulatory levels.

The development of the 7500 LC-MS system from SCIEX is bringing new levels of analytical sensitivity to researchers. To find out more about the system and the applications that could benefit, we spoke to Jack Steed, a technical specialist from SCIEX.

We spoke to Darlene Solomon to learn more about improving sustainability in science and Agilent’s commitment to My Green Lab and other sustainability initiatives.

This article discusses how semi-automation drastically improved the accuracy and precision of the lab’s results, and freed up its busy scientists to run other vital tests that had temporarily been forced to take a backseat.

In this interview, we speak to Dr. Simon Chandler, CEO of Rinri Therapeutics, to learn more about a new surgical method of accessing the human cochlea which could pave the way for new therapies for hearing loss.

In this interview, we speak to Vikram Devgan at NanoString Technologies to learn more about how added context from spatial biology techniques can provide more detailed insights during tissue analysis.

There remains an active debate within the psychedelic community about the importance of psychedelic experiences to these drugs’ therapeutic effects. Delix Therapeutics is developing compounds, called psychoplastogens, that act similarly to psychedelic compounds at the molecular level but do not induce hallucinations. We spoke with the Delix team to find out more about their research's progress.